We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we ...

Cytokinetics (CYTK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

Cytokinetics has a strong cash runway but faces risks from its Royalty Pharma deal. Read more on what's ahead for this ...

Cytokinetics is now rapidly moving into commercialization efforts with Aficamten. Read more to see why I rate CYTK stock a ...

Shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) were up 4.9% during mid-day trading on Friday . The company traded as high as $44.71 and last traded at $45.20. Approximately ...

Interactive Tool Harnesses Real-World Data to Visualize Burden of Disease in HCM and Advance Equitable Access to CareSOUTH SAN FRANCISCO, Calif., ...

March 17, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced five presentations related to aficamten, an investigational cardiac myosin inhibitor, and hypertrophic ...

Cytokinetics, Incorporated CYTK reported a net loss of $1.26 per share in the fourth quarter of 2024, wider than the Zacks Consensus Estimate of a loss of $1.22. In the year-ago quarter ...

In this article, we are going to look at where Cytokinetics, Incorporated (NASDAQ:CYTK) stands against other biotech stocks. The biotechnology sector is gaining new momentum with better market ...

Cytokinetics (CYTK) shares rallied 5.4% in the last trading session to close at $45.43. This move can be attributable to notable volume with a higher number of shares being traded than in a ...